Future Trajectory | Analysts project varied outcomes, with price targets ranging from $8 to $11, as Bausch Health navigates debt challenges and growth opportunities |
Strategic Maneuvers | Delve into Bausch Health's initiatives to maximize shareholder value, including the potential separation of its Bausch+Lomb division |
Debt Dilemma | Explore the company's $21.5 billion debt burden and its impact on financial stability, including market reactions to potential bankruptcy rumors |
Financial Resilience | Bausch Health's Q3 2024 results showcase robust growth, with revenues of $2.51 billion and a 12% year-over-year increase, surpassing analyst expectations |
Metrics to compare | BHC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBHCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | 11.6x | −0.4x | |
PEG Ratio | 0.00 | 0.09 | 0.00 | |
Price / Book | −0.9x | 1.4x | 2.6x | |
Price / LTM Sales | 0.2x | 2.1x | 3.0x | |
Upside (Analyst Target) | 42.6% | 32.1% | 51.9% | |
Fair Value Upside | Unlock | 22.0% | 9.4% | Unlock |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.